Weill Medical College of Cornell University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Weill Medical College of Cornell University sits in the top decile of US sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count).

701 total trials 127 currently recruiting 387 completed early-phase tilt top decile by trial count

Weill Medical College of Cornell University: 701 sponsored US clinical trials, 127 recruiting.

Weill Medical College of Cornell University sponsors 701 registered US clinical trials on ClinicalTrials.gov, 127 of them currently recruiting, and 387 completed. 89 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 20 trials.

Top-decile sponsor footprint

Weill Medical College of Cornell University ranks in the top decile of sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

387 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

701 total, page 10 of 15

COMPLETED

Analysis of Stroke Rehabilitation Outcomes

NCT02876783

COMPLETED

Incident COronary EveNts Identified by Computed Tomography

NCT02959099

COMPLETED Phase 4

Emotional and Cognitive Control in Late-Onset Depression

NCT01728194

COMPLETED NA

Comparing Paper-based and Tablet-delivered Informed Consent for Older Adults

NCT02114970

TERMINATED Phase 2

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01779167

COMPLETED

Outcome Analysis for Minimally Invasive Spine Surgery and Navigation

NCT01751841

TERMINATED Phase 4

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

NCT01632202

TERMINATED NA

FemVue and Tubal Patency

NCT01880073

COMPLETED Phase 1

Intra-arterial Chemotherapy for Spinal Metastases

NCT01637766

COMPLETED

Regulation of Stem Spermatogonia in the Mature Testis

NCT02756923

COMPLETED Phase 1

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

NCT01767415

COMPLETED Phase 2

Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL

NCT01125176

COMPLETED NA

Ecosystem Focused Therapy in Post Stroke Depression

NCT01624402

COMPLETED NA

Open Treatment of Minocycline in Geriatric Depression

NCT01659320

COMPLETED NA

Psychotherapy for Late Life Depression

NCT01698255

TERMINATED NA

Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery

NCT01558128

TERMINATED NA

In Vitro Maturation (IVM) of Human Oocytes

NCT01550861

COMPLETED Phase 1

Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy

NCT01407809

COMPLETED Phase 1

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

NCT01470027

COMPLETED Phase 1

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

NCT01581411

COMPLETED

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

NCT01974232

TERMINATED

Collection of Cerebrospinal Fluid in Healthy Children

NCT01698229

COMPLETED Phase 4

Sustaining Remission of Psychotic Depression

NCT01427608

COMPLETED NA

Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of OSA With CPAP

NCT01909674

COMPLETED

Longitudinal Survey Analysis in Lymphoma Survivors

NCT01469754

COMPLETED NA

Polar Body Biopsy for Preimplantation Genetic Screening

NCT01574404

COMPLETED NA

Follicular Flushing

NCT01558141

TERMINATED

Brain Dynamics in Different Stages of Arousal and Anesthesia

NCT01574443

TERMINATED

Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.

NCT02168036

COMPLETED Phase 2

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

NCT01472562

COMPLETED Phase 2

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

NCT01401062

COMPLETED Phase 1

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

NCT01352650

COMPLETED Phase 1

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

NCT01386346

COMPLETED

Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization

NCT01147328

TERMINATED

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

NCT01386723

COMPLETED NA

Study of the Impact of a Hospital Discharge Care Coordination Program in an Elderly Population

NCT01440907

COMPLETED Phase 3

Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer

NCT01352637

TERMINATED Phase 1

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

NCT01338935

COMPLETED NA

Adapting Dialectical Behavior Therapy for Children in Residential Care

NCT01547052

COMPLETED

Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke

NCT02168673

COMPLETED

Usage of Health Information Exchange (HIE) Technologies

NCT01250288

COMPLETED NA

Home-delivered Intervention for Depressed, Cognitively Impaired Elders

NCT01350349

COMPLETED Phase 3

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

NCT01146834

TERMINATED Phase 2

Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

NCT01558492

COMPLETED NA

Personalized Antidepressant Adherence Strategies For Depressed Elders

NCT01301859

COMPLETED Phase 1

Intervention for Anxiety After Falls

NCT01268657

TERMINATED NA

Effectiveness of Celecoxib After Surgical Sperm Retrieval

NCT01323595

TERMINATED

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

NCT02050581

COMPLETED NA

Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation

NCT01236326

TERMINATED Phase 4

Effect of Inhaled Steroids on Gene Expression in the Lungs - 2

NCT00826748

← Previous Page 10 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 111
Phase 3 26
Phase 4 63

What is open in the Weill Medical College of Cornell University pipeline

127 recruiting of 701 indexed (18% open); 387 completed (55%).

Phase mix: 89 late (III/IV) vs 197 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Weill Medical College of Cornell University: open-pipeline peers nationwide

Peers matched on 701 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Weill Medical College of Cornell UniversityIcahn School of Medicine at Mount SinaiSanofiThe Cleveland ClinicUniversity of MiamiChildren's Hospital of PhiladelphiaUniversity of California, BerkeleyBurke Medical Research InstituteGrand Valley State University
Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 701 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Weill Medical College of Cornell University page

701 registered trials is a research-attention snapshot, not an endorsement of Weill Medical College of Cornell University or any single study.

  • 127 of Weill Medical College of Cornell University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Weill Medical College of Cornell University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Weill Medical College of Cornell University pipeline card: 701 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.